
Teng Yu
Articles
-
Sep 8, 2024 |
mdpi.com | Rui Wang |Jiahao Ren |Weidong Li |Teng Yu
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Feb 11, 2024 |
nature.com | Teng Yu
AbstractAmidst the global digital transformation of educational institutions, digital technology has emerged as a significant area of interest among scholars. Such technologies have played an instrumental role in enhancing learner performance and improving the effectiveness of teaching and learning. These digital technologies also ensure the sustainability and stability of education during the epidemic.
-
Dec 22, 2023 |
jnm.snmjournals.org | Ying Miao |Runhua Feng |Teng Yu |Rui Guo
fibroblast activation protein inhibitorPET/CTneoadjuvant chemotherapylocally advanced gastric cancerIn patients with locally advanced gastric cancer (LAGC) before radical surgery, neoadjuvant chemotherapy (NAC) is increasingly being applied because it may help control focal lesions, downstage tumors, increase R0 resection rates, and improve the disease-free and overall survival of patients (1–4). However, the role of preoperative NAC in LAGC remains controversial (5,6).
-
Sep 28, 2023 |
mdpi.com | Linfeng Li |Jian Wang |Zhiming Chen |Teng Yu
Article Menu/ajax/scifeed/subscribeAltmetricannouncementHelpformat_quoteCitethumb_up... EndorseNeed Help? Find support for a specific problem in the support section of our website. Please let us know what you think of our products and services. Visit our dedicated information section to learn more about MDPI.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →